Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.98 |
| ▸ | HRH1 | P35367 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700496 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL156646 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL29754193 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL29870266 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL8733354 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL8731569 | 0.99 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL29407476 | 0.99 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL8731566 | 0.99 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL4913461 | 0.99 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4912732 | 0.97 | TACR1 (0.94) | TACR1CYP2D6KCNH2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441087-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2025-02-19 | — | — | EP | claimed |
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| EP-3441087-A1 | METHODS OF TREATING CHRONIC PAIN | Teva Pharmaceuticals International GmbH (CH) | 2019-02-13 | — | — | EP | claimed |
| EP-2265287-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2018-09-05 | — | — | EP | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| EP-3115062-A1 | METHODS OF TREATING INFLAMMATORY PAIN | Labrys Biologics Inc. (US) | 2017-01-11 | — | — | EP | claimed |
| US-20150037335-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2015-02-05 | — | — | US | claimed |
| EP-2825208-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | Levicept Ltd. (GB) | 2015-01-21 | — | — | EP | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| WO-2005102338-A1 | METHOD OF TREATING NEUROPATHIC PAIN USING A CRTH2 RECEPTOR ANTAGONIST | PFIZER LIMITED (GB) | 2005-11-03 | — | — | WO | claimed |
| US-20040167200-A1 | Pharmaceutical composition and method of modulating cholinergic function in a mammal | PFIZER INC. | 2004-08-26 | — | — | US | claimed |
| EP-1404320-A2 | A PHARMACEUTICAL COMPOSITION COMPRISING A NICOTINIC RECEPTOR PARTIAL ANTAGONIST AND AN ANTIEMETIC AGENT FOR MODULATING CHOLINERGIC FUNCTION | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| WO-2003005998-A2 | A PHARMACEUTICAL COMPOSITION COMPRISING A NICOTINIC RECEPTOR PARTIAL ANTAGONIST AND AN ANTIEMETIC AGENT OF MODULATING CHOLINERGIC FUNCTION | PFIZER PRODUCTS INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-20030008892-A1 | Pharmaceutical composition and method of modulating cholinergic function in a mammal | PFIZER INC. | 2003-01-09 | — | — | US | claimed |
| EP-1272218-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2001076576-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | claimed |
| US-5663349-A | Preparation of substituted piperidenes | PFIZER INC (US) | 1997-09-02 | — | — | US | claimed |
| EP-0619806-A1 | PREPARATION OF SUBSTITUTED PIPERIDINES. | PFIZER (US) | 1994-10-19 | — | — | EP | claimed |
| WO-1993011110-A1 | PREPARATION OF SUBSTITUTED PIPERIDINES | PFIZER INC. (US) | 1993-06-10 | — | — | WO | claimed |